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Summary
 
Anti–neutrophil cytoplasmic antibodies (ANCAs) targeting proteinase 3 (PR3) have a high
specifity for Wegener’s granulomatosis (WG), and their role in activating leukocytes is well ap-
preciated. In this study, we investigated the influence of PR3-ANCA and murine monoclonal
antibodies on human umbilical vascular endothelial cells (HUVECs). Priming of HUVECs
with tumor necrosis factor 
 
a
 
 induced endothelial upregulation of PR3 message and surface ex-
pression of this antigen, as measured by Cyto-ELISA, with a maximum occurrence after 2 h.
Primed cells responded to low concentrations of both antibodies (25 ng–2.5 
 
m
 
g/ml), but not to
control immunoglobulins, with pronounced, dose-dependent phosphoinositide hydrolysis, as
assessed by accumulation of inositol phosphates. The signaling response peaked after 20 min, in
parallel with the appearance of marked prostacyclin and platelet-activating factor synthesis. The
F(ab)
 
2
 
 fragment of ANCA was equally potent as ANCA itself. Disrupture of the endothelial
F-actin content by botulinum C2 toxin to avoid antigen–antibody internalization did not affect
the response. In addition to the metabolic events, anti-PR3 challenge, in the absence of plasma
components, provoked delayed, dose-dependent increase in transendothelial protein leakage.
We conclude that anti-PR3 antibodies are potent inductors of the preformed phosphoinositide
hydrolysis–related signal tranduction pathway in human endothelial cells. Associated metabolic
events and the loss of endothelial barrier properties suggest that anti-PR3–induced activation of
endothelial cells may contribute to the pathogenetic sequelae of autoimmune vasculitis charac-
terizing WG.
 
T
 
he diagnosis of Wegener’s granulomatosis (WG),
 
1
 
 a
systemic vasculitis that may affect several organs and
has poor prognosis in full-blown cases, has largely profited
from the discovery of anti–neutrophil cytoplasmic antibod-
ies (ANCAs; references 1, 2). Based on immunofluorescence
patterns, the cytoplasmic (classic) ANCA (c-ANCA), tar-
geting proteinase 3 (PR3) contained in azurophilic granules
(3, 4), and the perinuclear ANCA, brought about by anti-
myeloperoxidase antibodies (5, 6), are distinguished. The
presence of c-ANCA has a nearly 95% specificity for WG,
and the titer correlates well with disease activity (7, 8). Ad-
ditional autoantigenic ANCA targets have recently been iden-
tified (9).
Besides being a seromarker of WG, there is now good
evidence for a pathogenetic role of c-ANCA. When being
primed with cytokines, as occurs in episodes of infection or
inflammation, neutrophils express PR3 on their surface,
which thus becomes accessible to autoantibody binding
(10–13). In vitro studies demonstrated that such binding
provokes respiratory burst and degranulation (6, 12, 14,
15), and these inflammatory events are largely amplified in
the presence of free arachidonic acid assumed to arise in the
microenvironmental milieu of an inflammatory focus (16).
 
1
 
Abbreviations used in this paper:
 
 ANCA, anti–neutrophil cytoplasmic anti-
bodies; c-ANCA, cytoplasmic ANCA; HUVEC, human umbilical cord
endothelial cell; IP, inositol phosphate; IPx, IP1, IP2, and IP3; MoAb-
PR3, mAb to proteinase 3; PAF, platelet-activating factor; PR3, protein-
ase 3; WG, Wegener’s granulomatosis.
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These findings suggest that endothelial cell stimulation
and injury, a hallmark of WG’s granulomatosis, may be a
consequence of antibody-related neutrophil activation, as
reproduced in vitro and in experimental studies (17–19). Re-
cently, however, evidence was presented that PR3, the tar-
get antigen of c-ANCA, may also be present on the surface
of endothelial cells under conditions of cytokine priming (20).
Moreover, the data clearly supported the notion that the
endothelial PR3 surface expression was not due to binding
of exogenous PR3, but to upregulation of endogenous
PR3 synthesis and its transfer to the endothelial cell surface.
Admixture of anti-PR3 antibodies to such cells caused en-
hanced expression of the adhesion molecules endothelial
leukocyte adhesion molecule 1 (ELAM-1) (21) and vascu-
lar cell adhesion molecule 1 (VCAM-1) (22), which might
again favor interaction with leukocytes. Using c-ANCA–
positive serum from WG patients and an mAb manufactured
against human PR3 (MoAB-PR3), we now investigated
anti-PR3–related alterations in human endothelial cell bi-
ology in more detail. Interestingly, pronounced activation
of the phosphoinositide hydrolysis-related signal transduc-
tion pathway was noted, alongside with induction of lipid
mediator generation. In addition, barrier properties of the
endothelial cell monolayer, assessed in the absence of plasma
components and neutrophils, were progressively lost. These
data suggest that hitherto not recognized direct endothelial
cell activation by c-ANCA may contribute to the develop-
ment of vascular injury in WG. 
 
Materials and Methods
 
Preparation of Human Umbilical Vascular Endothelial Cells.
 
Isola-
tion and culturing were performed as previously described (23,
24). Cells of 10 donors were pooled to exclude the influence of
blood group antigens. Morphology was confirmed by phase-con-
trast light microscopy (cobblestone monolayer appearance), and
purity was tested with antibodies to von Willebrand’s factor.
 
Antibody Preparation.
 
Human MoAb-PR3s were prepared as
previously described (11); controls were performed with murine
mAb IgG, isotype control (Dianova, Hamburg, Germany). Anti-
bodies originating from pooled serum of five patients with mono-
specific anti-PR3 antibody-positive–established WG were puri-
fied by adsorption on a PR3 affinity column as described (20). The
absorbed IgG fraction (ANCA), displaying a high anti-PR3 titer,
was diluted to result in final IgG concentrations of 250 ng/ml in
all experiments. When preparing the F(ab)
 
2
 
 fragment of ANCA
(ANCA-F[ab]
 
2
 
), its purity was checked to range above 95% by
SDS-PAGE, and a final concentration of 250 ng/ml was used
throughout. Control human IgG
 
1
 
, again used at 250 ng/ml, orig-
inated from pooled serum of 100 healthy donors. Murine mAbs
to human thrombomodulin were a gift from Dr. B. Pötzsch
(Max-Planck-Institute, Bad Nauheim, Germany). All antibody prep-
arations were checked for absence of endotoxin by a commercially
available E-toxate assay (Sigma Chemical Co., München, Germany).
 
Detection of PR3 on Endothelial Cell Membrane.
 
PR3 expression
on endothelial cell surface was quantified by Cyto-ELISA with
unfixed human umbilical vascular endothelial cells (HUVECs) as
described (20).
 
Detection of PR-3 Messenger RNA in HUVECs by PCR Tech-
nique.
 
The RNA preparation of cells was performed with the
 
Fast Track
 
Ô
 
 RNA–Isolation Kit (Boehringer Mannheim GmbH,
Mannheim, Germany). The PR3 cDNA was synthesized by the
reverse transcriptase PCR in a hybrid thermocycler (Uno-Ther-
moblock; Biometra, Goettingen, Germany). The sequence of the
3
 
9
 
 primer was GCGGCGAGGGACGAAACTGCA and of the
5
 
9
 
 primer was ATCGTGGGCGGGCACGAGGCG. The ampli-
ficated cDNA had a length of 501 bp. The amplification of the PR3
cDNA was performed according to the following program: dena-
turation (94
 
8
 
C for 5 min), 30 cycles of amplification (94
 
8
 
C for 1
min, 58
 
8
 
C for 1.5 min, 72
 
8
 
C for 2 min), and termination at 72
 
8
 
C
for 5 min. DNA fragments were separated in a 1.5% agarose gel.
 
Measurement of Endothelial Barrier Function.
 
Albumin flux through
endothelial monolayer was taken as marker of endothelial barrier
function and quantified in a two-compartment system using
FITC-labeled albumin as previously described (25). In separate
control experiments, antibody binding to HUVEC was provoked
by admixture of various concentrations of antithrombomodulin
antibodies.
 
Analytical Procedures.
 
For assessment of platelet-activating fac-
tor (PAF) generation, the total cellular and extracellular PAF con-
tent was lipid extracted, subjected to HPLC separation, and quan-
tified by induction of [
 
3
 
H]serotonin release from prelabeled rabbit
platelets as described (26). To convert [
 
3
 
H]serotonin release into
absolute PAF concentration, calibration with exogenous PAF was
performed. The phosphatidylinositol (PtdIns) turnover was inves-
tigated by measuring the accumulation of inositol phosphates ac-
cording to Berridge (27). For prelabeling of cellular phospholipid
pools, HUVECs were seeded on culture plates with an area of 4
cm
 
2
 
/well (
 
z
 
300 cells/mm
 
2
 
) in medium 199 containing 10% fetal
calf serum plus 40 mM Hepes buffer, pH 7.4. Myo-[
 
3
 
H]inositol
(5 
 
m
 
Ci/ml) was added, and cells were incubated at 37
 
8
 
C for 24 h
in an atmosphere of 95% O
 
2
 
 and 5% CO
 
2
 
. Before experimental
use, cells were washed twice and kept in Hanks’ balanced salt so-
lution containing 20 mM Hepes and 10 mM LiCl. At different
times after stimulus application, samples were quenched with
trichloracetic acid (final concentration 7.5%), kept on ice for 15
min, and extracted four times with diethylether. The aqueous
phase was neutralized with sodium tetraborate to pH 8.0, and
processed to separate inositol phosphates on Dowex anion ex-
change columns as described by Berridge (27). The column was
eluted sequentially with water (for free [
 
3
 
H]inositol), 5 mM Na-
tetraborate/60 mM Na-formate (for glycerophospho-[
 
3
 
H]inosi-
tol), 0.1 M formic acid/0.2 M ammonium formate (for [
 
3
 
H]IP
 
1
 
),
0.1 M formic acid/0.5 M ammonium formate (for [
 
3
 
H]IP
 
2
 
), and
0.1 M formic acid/1.0 M ammonium formate (for [
 
3
 
H]IP
 
3
 
), and
samples were processed for liquid scintillation counting.
Buffer concentrations of 6-keto-prostaglandin F
 
1
 
a
 
, the stable
metabolite of prostacyclin, were assayed by solid phase extraction
and post-HPLC ELISA as described by our laboratory (28).
 
Experimental Procedures.
 
Confluent endothelial cell monolay-
ers of the first passage were taken for these experiments. In sepa-
rate control studies, fourth-passaged HUVECs were used. After
removal of cell culture medium by two washing steps, priming of
HUVECs with 4 ng recombinant TNF-
 
a
 
/ml (Boehringer Mann-
heim GmbH) incubated for 2 h, was performed. Cells were then
washed to remove TNF, and stimulation was undertaken with
MoAb-PR3 (25 ng, 250 ng, and 2.5 
 
m
 
g/ml), 250 ng/ml ANCA,
250 ng/ml ANCA-F(ab)
 
2
 
 or 250 ng/ml control immunoglobulin.
Botulinum C2 toxin, which is composed of a membrane trans-
location component (C
 
2II
 
) and a component (C
 
2I
 
) affecting ADP-
ribosylation of nonmuscle G-actin, thereby acting as a barbed
end–capping protein and effecting selective loss of the nonmuscle
F-actin content (29), was provided by K. Aktories (Freiburg, Ger- 
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many). It was coapplied with antibodies at a concentration of 200
ng/ml C
 
2I
 
 and 400 ng/ml C
 
2II
 
. All experiments were performed
in serum-free Hanks’ balanced salt solution; studies with PAF mea-
surement were undertaken in the presence of 0.25 mg/ml bovine
serum albumin. Reactions were stopped by centrifugation at 4
 
8
 
C
for 5 min at 1,200 
 
g.
Statistics.
 
For statistical comparison, one-way analysis of vari-
ance was performed. A level of 
 
P
 
 
 
,
 
0.05 was considered to be sig-
nificant.
 
Results
 
TNF preincubation of HUVECs caused a marked, time-
dependent increase in the surface expression of PR3, as as-
sessed by the binding of both monoclonal (MoAb-PR3)
and affinity-purified human antibodies (ANCA) to this tar-
get (Fig. 1). An optimum TNF priming period of 2 h was
identified for both antibodies. In contrast, the binding of
control IgG
 
1
 
 was not affected by preincubation of the en-
dothelial cells with this cytokine.
Using PCR technique, PR3 message was detected in
fourth-passaged HUVECs subsequent to TNF challenge
(Fig. 2), whereas PR3 messenger RNA was not detectable
in untreated HUVECs.
Corresponding with these kinetics, the sequence of TNF
priming and anti-PR3 challenge caused a pronounced up-
regulation of endothelial inositol phosphate formation (Figs.
3 and 4). A 2-h period was again identified as optimum
TNF priming time with respect to both MoAb-PR3 and
ANCA stimulation. As compared to baseline levels, the
sum of sequentially formed IP
 
1
 
, IP
 
2
 
, and IP
 
3
 
, collectively
depicted as IPx, increased up to fourfold. The antibody-
evoked phosphoinositide hydrolysis was evident within 5
min of MoAb-PR3 and ANCA admixture, and the maxi-
mum response occurred after 20 min, with subsequent de-
cline of IPx levels. The F(ab)
 
2
 
 fragment of ANCA dis-
played virtual identical efficacy as ANCA itself. In contrast,
control murine and human IgG was completely ineffective.
In separate experiments, fourth-passaged HUVECs were
used and corresponding PI hydrolysis in response to anti-
PR3 was obtained (Fig. 5).
Coexposure of HUVECs to MoAb-PR3 and botulinum
C2 toxin did not suppress the phosphoinositide response.
In experiments performed in one batch of endothelial cells,
25 ng/ml MoAb-PR3 elicited 725.3 
 
6
 
 52.4 cpm (10 min)
and 830 
 
6
 
 51.0 cpm (20 min) IPx in the absence of C2
toxin, as compared to 839 
 
6
 
 34.5 cpm (10 min) and 1,014 
 
6
 
62.1 cpm (20 min) in the presence of the toxin.
In parallel with the phosphoinositide hydrolysis, endo-
Figure 1. Influence of TNF priming on HUVEC PR3 presentation.
HUVECs were incubated with TNF (4 ng/ml) for various time periods
before addition of MoAb-PR3, ANCA, or control murine IgG1. Immu-
noglobulin binding to the cells was assessed by Cyto-ELISA, and optical
density is displayed. Mean 6 SEM of five independent experiments each
is given. Experiments with ANCA and MoAb-PR3 significantly differed
from the IgG1 control.
Figure 2. HUVEC PR3 messenger RNA upregulation in response to
TNF priming. Priming was performed with TNF-a (4 ng/ml), for 20
min. Primed HUVECs (lane a, PR-3, 501 bp; lane b, GAPDH) express
PR-3 in contrast to nonprimed cells (lane c, PR-3; lane d, GAPDH).
Lane e, negative control; lane f, marker (100 bp marker from Gibco, Egg-
enstein, Germany).
Figure 3. Influence of TNF-priming period on HUVEC activation by
anti-PR3 challenge. HUVECs were incubated with TNF (4 ng/ml) for
various time periods before addition of MoAb-PR3, ANCA, murine
control IgG1 (IgG1), or sham incubation (CONTROL). IP formation was
assessed 20 min after onset of antibody incubation. Mean 6 SEM of five
independent experiments each is given. Experiments with ANCA and
MoAb-PR3 significantly differed from control. In additional control ex-
periments with nonspecific human IgG, data (not displayed) did not differ
from control. 
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thelial PAF generation was provoked by the sequence of
TNF priming and anti-PR3 challenge (Fig. 6). The maxi-
mum metabolic response again occurred 20 min after anti-
body admixture; control IgG was completely ineffective.
Similarly, impressive stimulation of prostacyclin synthesis
was noted in TNF-primed endothelial cells undergoing
challenge with MoAb-PR3 (Fig. 7) and ANCA (data not
given in detail), but not with control IgG. As anticipated,
the prostanoid release reaction was completely abrogated in
the presence of acetylsalicylic acid.
The sequence of cytokine priming and anti-PR3 chal-
lenge resulted in a marked loss of endothelial barrier prop-
erties (Fig. 8). Stimulation of the monolayer with MoAb-
PR3 in the absence of TNF preincubation did not affect
the baseline albumin passage. TNF priming per se, fol-
lowed by stimulation with control IgG, resulted in some
marginal increase in protein flux. This was significantly in-
creased when TNF-primed HUVECs were incubated with
anti-PR3 mAbs. The time course of this response was,
however, slower compared to the metabolic events; the
Figure 4. Time course of IP accumulation in response to anti-PR3
challenge. After a priming period of 2 h with TNF (4 ng/ml), HUVECs
were challenged with MoAb-PR3, ANCA, ANCA-F(ab)2, or murine
control IgG1 (IgG1) for various time periods, or sham incubation was
performed (CONTROL). Data are given as mean 6 SEM of five inde-
pendent experiments. Experiments with ANCA, ANCA-F(ab)2, and
MoAb-PR3 significantly differed from control. In additional control ex-
periments with nonspecific human IgG, data (not displayed) did not differ
from control.
Figure 5. Effect of anti-PR3 on IP formation in fourth-passaged HU-
VECs. After a priming period of 2 h with TNF (4 ng/ml), HUVECs
of subculture 4 (P4) were challenged with different concentrations of
MoAb-PR3 for various time periods or sham incubated (CONTROL).
Data are given as mean 6 SEM of five independent experiments. Experi-
ments with the different concentrations of MoAb-PR3 significantly dif-
fered from control.
Figure 6. Time and dose dependency of PAF synthesis in response to
anti-PR3 challenge. After 2 h of TNF priming, HUVECs were chal-
lenged with different concentrations of MoAb-PR3, ANCA (only one time
point), or control murine IgG1. PAF synthesis is given in pmol PAF/ml
assay volume. Mean 6 SEM of five independent experiments each is de-
picted. Experiments with the different concentrations of MoAb-PR3 sig-
nificantly differed from control IgG1.
Figure 7. Prostaglandin I2 formation in response to MoAb-PR3. After
2 h of TNF priming, HUVECs were challenged with different concentra-
tions of MoAb-PR3, control murine IgG1, or were incubated in the ab-
sence of immunoglobulins (CONTROL). Prostanoid release into the cell
supernatant was quantified 20 min after antibody admixture. Gray col-
umns represent parallel samples preincubated with acetylsalicylic acid (10
mM) for 5 min. Mean 6 SEM of five independent experiments each is
given. Experiments with MoAb-PR3 in the absence of acetylsalicylic acid
significantly differed from control and nonspecific murine IgG1.501 Sibelius et al.
onset of leakage was evident after 50 min, and progressive
deterioration of barrier properties occurred up to the end
of the observation period (100 min). In separate control ex-
periments performed to probe the effect of non-PR3–
related surface antigen binding on permeability character-
istics of the endothelial monolayer, untreated HUVECs
were exposed to murine antithrombomodulin mAbs in
various concentrations (25 ng–25 mg/ml). This antibody is
known to bind to thrombomodulin, present in abundancy
on the cell surface of HUVECs (30, 31). None of these ex-
perimental conditions provoked any significant change in
albumin flux. In detail, 100 min after antibody admixture,
albumin flux was 103 6 8.8%, 105 6 6.4%, 97 6 10.1%,
and 101 6 9.6% of baseline in response to 25 ng/ml, 250
ng/ml, 2.5 mg/ml, and 25 mg/ml antithrombomodulin an-
tibody, respectively. The lack of HUVEC responsiveness
to antithrombomodulin antibodies was equally observed in
cells pretreated with 4 ng TNF/ml according to the stan-
dard protocol.
All MoAb-PR3–induced metabolic changes as well as
the leakage response displayed a maximum upon use of 250
ng/ml mAb, with lower efficacy of both 25 ng and 2.5
mg/ml. In contrast, PAF synthesis was found to be maximal
at 2.5 mg/ml MoAb-PR3. This difference is most probably
explained by the fact that albumin was admixed to the me-
dium in case of PAF measurement, thus reflecting antibody
binding by the serum protein.
Discussion
It has previously been shown that priming of human
neutrophils with cytokines such as TNF-a induces a trans-
location of PR3 from the azurophilic granules to the cellu-
lar surface (10–13). In the case of endothelial cells, how-
ever, the origin of PR3 is much less obvious. Circulating
free PR3 has been shown to bind to the surface of these
cells (32); however, all solutions currently used were tested
to be devoid of PR3, including the cell culture medium.
PR3 was shown to be present in the cytoplasm of un-
treated cultured endothelial cells by confocal laser scanning
microscopy (20), and in correspondence with this preced-
ing study the current Cyto-ELISA data, using two different
specific anti-PR3 antibodies, leave no doubt that the TNF
exposure results in endothelial surface expression of this an-
tigen. In addition, TNF-elicited appearance of PR3 message
in the endothelial cells was demonstrated in this study.
When compared to studies with antiendothelial antibod-
ies purified from scleroderma patients (33, 34), which used
antibody doses of z100 mg/ml to effect endothelial cell
activation, strikingly low concentrations of ANCA (250
ng/ml) and MoAb-PR3 (25 ng–2.5 mg/ml) currently suf-
ficed to provoke marked signaling and metabolic events in the
human endothelial cells. The phosphoinositide hydrolysis
affected by both antibodies peaked in parallel with the TNF-
evoked presentation of PR3, and its magnitude approached
that known to be provoked by thrombin, the most potent
activator of the phosphatidylinositol response in endothelial
cells hitherto described (35). Via IP3-affected calcium lib-
eration, this signaling sequence is linked to activation of
phospholipolytic pathways with subsequent generation of
prostacyclin and PAF. It is in line with this reasoning that
the time course of both prostanoid and PAF synthesis paral-
leled the kinetics of phosphoinositide hydrolysis in the cur-
rent study.
The link between antibody binding and triggering of phos-
phoinositide hydrolysis is, however, much less obvious. Re-
ceptor/antigen cross-linking and the involvement of Fc re-
ceptors may be excluded, as the F(ab)2 fragment of ANCA
turned out to be equally potent as ANCA itself. This is also
true for complement receptors, as the experiments were
performed in the absence of complement sources. More-
over, phenomena of internalization of the antigen–anti-
body complex are unlikely to be enrolled, as disrupture of
the endothelial F-actin content with botulinum C2-toxin
(36) did not suppress the phosphoinositide hydrolysis. Thus,
monomeric IgG ligand binding must be assumed to suffice
for signal transduction. Interestingly, activation of phos-
phoinositide hydrolysis was not observed after antithrom-
bomodulin challenge used as control antibody targeting an
abundant endothelial surface antigen. Further studies are
required to elucidate the mechanism by which the anti-
PR3 binding is linked to phospholipase C activation and
thus phosphatidylinositol hydrolysis.
In addition to the metabolic responses, incubation of hu-
man endothelial cells with anti-PR3 antibodies evoked a
marked increase in transendothelial protein leakage. Such
Figure 8. Time and dose dependency of anti-PR3 induced loss of en-
dothelial barrier function. After 2 h of TNF priming, HUVECs were
challenged with different concentrations of MoAb-PR3 or control mu-
rine IgG1. In separate control experiments, MoAb-PR3 (250 ng/ml) was
admixed to HUVECs undergoing sham priming in the absence of TNF.
Albumin flux through the endothelial monolayer is displayed in percent
of baseline value; 100% corresponds to permeability of (9.8 6 0.75) 3
1026 cm/s of barrier formed by TNF-primed HUVEC monolayer and
supporting filter membrane and to (8.3 6 0.58) 3 1026 cm/s to barrier
formed by untreated HUVEC monolayer and supporting filter mem-
brane. Mean 6 SEM of five independent experiments each is given. The
experiments with 250 ng/ml and 25 ng/ml MoAb-PR3 significantly dif-
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loss of barrier properties has previously not been described
for antiendothelial antibodies encountered in human dis-
ease. The leakage response presented with an identical dos-
age optimum of MoAb-PR3 as the phosphoinositide hy-
drolysis, thus suggesting a link between these two events. It
did, however, demand a much longer latent period (.30
min) as compared to the IPx accumulation (maximum after
20 min), suggesting that it is not simply linked to IP3-related
calcium increase and associated rapid contractile events (37).
This provocative part of the endothelial response to anti-
PR3 challenge thus also demands further elucidation.
In conclusion, priming of human endothelial cells with
TNF and exposure to specific anti-PR3 antibodies is capa-
ble of triggering a central signaling cascade in these cells, in
companion with lipid mediator generation and loss of en-
dothelial barrier properties. These findings refute the ex-
clusiveness of PMNs and monocytes as targets of anti-PR3
in instrumenting vascular injury in WG. The preconditions
for endothelial cell activation and leakage response, being
the presence of both autoantibodies and circulating cyto-
kines, may well occur in vivo under circumstances of infec-
tion or due to the autoantigenic process itself once it is trig-
gered. In accordance, TNF, interleukin 6, and interleukin
8 levels are known to be elevated in WG patients in active
disease, but are not detectable in remission (38, 39). The
current findings, identifying endothelial cells as active par-
ticipants rather than innocent bystanders in the scenario of
leukocyte–endothelium interaction, further support and
substantially extend the concept that c-ANCAs represent
not only the best seromarker for WG so far available, but
are centrally involved in the pathogenic sequelae of this
enigmatic disease.
Address correspondence to Dr. F. Grimminger, Department of Internal Medicine, Justus-Liebig-University
Giessen, D-35392 Giessen, FRG. Phone: 49-641-99-42500; Fax: 49-641-99-42509; E-mail: friedrich.
grimminger@innere.med.uni-giessen.de
Received for publication 3 July 1997 and in revised form 1 December 1997.
References
1. Hagen, E., B.E.P.B. Bailleux, L.A. van Es, M.R. Daha, and
F.J. van der Woude. 1993. Antineutrophil cytoplasmatic anti-
bodies: a review of the antigens involved, the assays, and the
clinical and possible pathogenetic consequences. Blood. 82:
1996–2002.
2. Kallenberg, C.J.M., E. Brouwer, A.H.L. Mulder, C.A. Steg-
mann, J.J. Weening, and J.W. Cohen Tervaert. 1995. ANCA–
pathophysiology revisited. Clin. Exp. Immunol. 100:1–3.
3. Lüdemann, J., B. Utecht, and W.L. Gross. 1990. Anti-neu-
trophil cytoplasm antibodies in Wegener’s granulomatosis rec-
ognize an elastinolytic enzyme. J. Exp. Med. 171:357–362.
4. Jenne, D.E., J. Tschopp, B. Utecht, and W.L. Gross. 1990.
Wegener’s autoantigen decoded. Nature. 346:520.
5. Falk, R.J., and J.C. Jennette. 1988. Anti-neutrophil cytoplas-
matic autoantibodies with specificity for myeloperoxidase in
patients with systemic vasculitis and idiopathic necrotizing
and crescentic glomerulonephritis. N. Engl. J. Med. 318:1651–
1657.
6. Falk, R.J., R.S. Terrell, L.A. Charles, and J. Charles Jennette.
1990. Anti-neutrophil cytoplasmatic autoantibodies induce neu-
trophils to degranulate and produce oxygen radicals in vitro.
Proc. Natl. Acad. Sci. USA. 87:4115–4119.
7. Van der Woude, F.J., S. Lobatto, H. Permin, M. van der
Giessen, N. Rasmussen, A. Wiik, L.A. van Es, and G.K. van
der Hem. 1985. Autoantibodies against neutrophils and mono-
cytes: tool for diagnosis and marker of disease activity in We-
gener’s granulomatosis. Lancet. 1:425–429.
8. Nölle, B., U. Specks, J. Lüdemann, M.S. Rohrbach, R.A.
DeRemee, and W.L. Gross. 1989. Anticytoplasmatic autoan-
tibodies: their immunodiagnostic value in Wegener’s granu-
lomatosis. Ann. Intern. Med. 111:28–40.
9. Kain, R., K. Matsui, M. Exner, S. Binder, G. Schaffner, E.V.
Sommer, and D. Kerjaschki. 1995. A novel class of autoanti-
gens of anti-neutrophil cytoplasmic antibodies in necrotizing
and crescentic glomerulonephritis: the lysosomal membrane
glycoprotein h-lamp-2 in neutrophil granulocytes and a re-
lated membrane protein in glomerular endothelial cells. J.
Exp. Med. 181:585–597.
10. Csernok, E., M. Ernst, W. Schmitt, D.F. Bainton, and W.L.
Gross. 1994. Activated neutrophils express proteinase 3 on
their plasma membrane in vitro and in vivo. Clin. Exp. Immu-
nol. 95:244–250.
11. Csernok, E., J. Lüdemann, W.L. Gross, and D.F. Bainton.
1990. Ultrastructural localization of proteinase 3, the target
antigen of anti-cytoplasmic antibodies circulating in Wege-
ner’s granulomatosis. Am. J. Pathol. 137:1113–1120.
12. Charles, L.A., M.L.R. Caldas, R.J. Falk, R.S. Terrell, and
J.C. Jennette. 1991. Antibodies against granule proteins acti-
vate neutrophils in vitro. J. Leukocyte Biol. 50:539–546.
13. Mulder, A.H., J. Broekroelofs, G. Horst, P.C. Limburg, G.F.
Nelis, and C.G. Kallenberg. 1994. Anti-neutrophil cytoplas-
matic antibodies (ANCA) in inflammatory bowel disease: char-
acterization and clinical correlates. Clin. Exp. Immunol. 95:
490–497.
14. Keogan, M.T., V.L. Esnault, A.J. Green, C.M. Lockwood,
and D.L. Brown. 1992. Activation of normal neutrophils by
anti-neutrophil cytoplasm antibodies. Clin. Exp. Immunol. 90:
228–234.
15. Mulder, A.H.L., P. Heeringa, E. Brouwer, P.C. Limburg,
and C.G.M. Kallenberg. 1994. Activation of granulocytes by
anti-neutrophil-cytoplasmatic antibodies (ANCA): a FcgRII-
dependent process. Clin. Exp. Immunol. 98:270–278.
16. Grimminger, F., K. Hattar, C. Papavassilis, B. Temmesfeld,
E. Csernok, W.L. Gross, W. Seeger, and U. Sibelius. 1996.
Neutrophil activation by anti–proteinase 3 antibodies in We-
gener’s granulomatosis: role of exogenous arachidonic acid503 Sibelius et al.
and leukotriene B4 generation. J. Exp. Med. 184:1567–1572.
17. Savage, C.O.S., B.E. Pottinger, G.Gaskin, C.D. Pusey, and
J.D. Pearson. 1992. Autoantibodies developing to myeloper-
oxidase and proteinase 3 in systemic vasculitis stimulate neu-
trophil cytotoxicity towards cultured endothelial cells. Am. J.
Pathol. 141:335–342.
18. Brouwer, E., M.G. Huitema, P.A. Klok, H. de Weerd, J.W.
Cohen Tervaert, J.J. Weening, and C.G.M. Kallenberg. 1993.
Antimyeloperoxidase-associated proliferative glomerulonephri-
tis: an animal model. J. Exp. Med. 177:905–914.
19. Mayet, W.J., A. Schwarting, and K.H. Meyer zum Büschen-
felde. Cytotoxic effects of antibodies to proteinase 3 (C-ANCA)
on human endothelial cells. Clin. Exp. Immunol. 97:458–465.
20. Mayet, W.J., E. Csernok, C. Szymkowiak, W.L. Gross, and
K.H. Meyer zum Büschenfelde. 1993. Human endothelial cells
express proteinase 3, the target antigen of anticytoplasmatic
antibodies in Wegener’s granulomatosis. Blood. 82:1221–1229.
21. Mayet, W.J., and K.H. Meyer zum Büschenfelde. 1993. An-
tibodies to proteinase 3 increase adhesion of neutrophils to
human endothelial cells. Clin. Exp. Immunol. 94:440–446.
22. Mayet, W.J., A. Schwarting, T. Orth, R. Duchmann, and
K.H. Meyer zum Büschenfelde. 1996. Antibodies to protein-
ase 3 mediate expression of vascular cell adhesion molecule–1
(VCAM-1). Clin. Exp. Immunol. 103:259–267.
23. Jaffe, E.A., R.L. Nachmann, and C.G. Becker. 1973. Culture
of human endothelial cells derived from umbilical veins: iden-
tification by morphological criteria. J. Clin. Invest. 52:2745–
2750.
24. Thornton, S.C., S.N. Mueller, and E.M. Levine. 1983. Hu-
man endothelial cells: use of heparin in cloning and long-
term serial cultivation. Science. 222:623–625.
25. Noll, T., A. Muhs, M. Besselmann, H. Watanabe, and M.
Piper. 1995. Initiation of hyperpermeability in energy-depleted
coronary endothelial monolayers. Am. J. Physiol. 268:H1462–
H1470.
26. Grimminger, F., U. Sibelius, S. Bhakdi, N. Suttorp, and W.
Seeger. 1991. Echerichia coli hemolysin is a potent inductor of
phosphoinositide hydrolysis and related metabolic responses
in human neutrophils. J. Clin. Invest. 88:1531–1539.
27. Berridge, M.J., R.M.C. Dawson, C.P. Downes, J.P. Heslop,
and R.F. Irvine. 1983. Changes in levels of inositol phos-
phates after agonist-dependent hydrolysis of membrane phos-
phoinositides. Biochem. J. 212:473–482.
28. Krämer, H.J., J. Stevens, and W. Seeger. 1993. Analysis of 2-
and 3-series prostanoids by post-HPLC ELISA. Anal. Bio-
chem. 214:535–543.
29. Aktories, K., M. Bärmann, I. Ohisi, S. Tsukayama, K.H. Ja-
kobs, and E. Habermann. 1986. Botulinum C2 toxin ADP-
ribosylates actin. Nature. 322:390–392.
30. Pötzsch, B., B. Kropp, H. Hausbruck, and G. Mueller-
Berghaus. 1997. Detection of circulating thrombin–throm-
bomodulin complexes in human plasma. Ann. Hematol. 74:366.
31. Horvat, R., and G.E. Palade. 1993. Thrombomodulin and
thrombin localization on the vascular endothelium; their in-
ternalization and transcytosis by plasmalemmal vesicles. Eur.
J. Cell Biol. 61:299–313.
32. Bailleux, P.E.P.B., K.T. Zondervan, P. Kievit, C. Hagen,
L.A. van Es, F.J. van der Woude, and M.R. Daha. 1994. Bind-
ing of proteinase 3 and myeloperoxidase to endothelial cells:
ANCA-mediated endothelial damage through ADCC? Clin.
Exp. Immunol. 97:52–60.
33. Carvallho, D., C.O.S. Savage, C.M. Black, and J.D. Pearson.
1996. IgG Antiendothelial cell autoantibodies from Sclero-
derma patients induce leukocyte adhesion to human vascular
endothelial cells. J. Clin. Invest. 97:111–119.
34. Simantov, R., J.M. LaSala, S.K. Lo, A.E. Gharavi, L.R. Sam-
maritano, J.E. Salmon, and R.L. Silverstein. 1995. Activation
of cultured vascular endothelial cells by antiphospholipid an-
tibodies. J. Clin. Invest. 96:2211–2219.
35. Davies, M.G., and P.O. Hagen. 1993. The vascular endothe-
lium: a new horizon. Ann. Surg. 218:593–609.
36. Grimminger, F., U. Sibelius, K. Aktories, I. Just, and W. See-
ger. 1991. Suppression of cytoskeletal rearrangement in acti-
vated human neutrophils by Botulinum C2 toxin. J. Biol.
Chem. 226:19276–19282.
37. Lum, H., J.L. Aschner, P.G. Phillips, P.W. Fletcher, and A.B.
Malik. 1992. Time course of thrombin-induced increase in
endothelial permeability: relationship to Ca21 and inositol-
polyphosphates. Am. J. Physiol. 263:L219–L225.
38. Gross, W.L., E. Csernok, and B.K. Flesch. 1993. ‘Classic’
anti-neutrophil cytoplasmatic autoantibodies (cANCA), ‘We-
gener’s autoantigen’ and their immunopathogenic role in
Wegener’s granulomatosis. J. Autoimmun. 6:171–184.
39. Ewert, H.B., J.C. Jennette, and R.J. Falk. 1991. The patho-
genic role of antineutrophil cytoplasmatic autoantibodies. Am.
J. Kidney Dis. 18:188–195.